Latest Therapeutic Antibodies News

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.